title: Eosinophilia--A rare possible adverse reaction during anti-tumor necrosis factor-alpha therapy for psoriasis.
abstract: The current use of tumor necrosis factor (TNF)-alpha inhibitors in rheumatological, dermatological and gastroenterological diseases has increased considerably in recent years. Different reports have been communicated regarding specific risks and side effects during treatment with TNF-alpha inhibitors. Eosinophilia has been linked to TNF-alpha inhibitors by several recent reports, although it is not listed as a possible adverse reaction in the product information of the drug. The aim of the present study was to evaluate the eosinophil count in patients diagnosed with psoriasis and treated with adalimumab. Based on the results of the present study, eosinophilia remains a rare adverse reaction during psoriasis treatment with TNF-alpha antagonists.
authors: a Department of Dermato-Physiology , Apollonia University , Iasi , Romania .|b Department of Dermatology , Nicolina Medical Center , Iasi , Romania .|c "P. Poni" Institute of Macromolecular Chemistry , Iasi , Romania .
authors: Anca
authors: A
authors: Chiriac
authors: d Department of Dermatology , 6th Military Support Unit , Ustka , Poland .
authors: Piotr
authors: P
authors: Brzezinski
authors: e Department of Pathology .
authors: Simona
authors: S
authors: Stolnicu
authors: f Department of Cardiology .
authors: Cristian
authors: C
authors: Podoleanu
authors: g Department of Histology , and.
authors: Cosmin
authors: C
authors: Moldovan
authors: h Department of Surgery , University of Medicine and Pharmacy of Targu Mures , Romania , and.
authors: Calin
authors: C
authors: Molnar
authors: i Department of Dermatology , University of Medicine and Pharmacy "Gr. T. Popa" Iasi , Romania.
authors: Tatiana
authors: T
authors: Taranu
mesh_terms: D000068879:Adalimumab / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use; D004802:Eosinophilia / Q000139:chemically induced*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy*; D012189:Retrospective Studies; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab
keywords: Adalimumab; adverse reaction; laboratory